MRUS Price Prediction Next Week
Analysis and Insights
Technical Analysis:
MRUS is currently trading at $48.69, with a pre-market gain of +5.08% and a regular market gain of +3.07%. The stock has shown strong momentum, with the MACD indicator showing a positive signal line crossover, suggesting bullish momentum. The RSI_14 is at 55.76, indicating the stock is not overbought, while the Stochastic Oscillator is at 62.49, showing potential for further upside.
News Sentiment and Analyst Ratings:
Analysts have a Strong Buy consensus on MRUS, with a price target of $88.83, indicating significant upside potential. Recent analyst upgrades and positive commentary on the company's pipeline and financial performance further support the bullish outlook.
Price Prediction:
Based on the technical indicators and analyst sentiment, MRUS is expected to trade between $47.50 and $50.30 in the next trading week. The stock is likely to test the upper resistance level of $50.30, with a potential breakout if momentum continues.
Recommendation:
Buy MRUS with a target price of $50.30 and a stop-loss at $47.50.
MRUS Similar Chart Price Prediction
The price of MRUS is predicted to go up -4.08%, based on the high correlation periods with CACC. The similarity of these two price pattern on the periods is 97.06%.
MRUS
CACC
Down: -4.08%Similarity: 97.06%
MRUS Revenue Forecast
MRUS EPS Forecast
MRUS FAQs
What is MRUS revenue forecast for next quarter？
What is MRUS eps forecast for next quarter？
MRUS Analyst's Forecast
Joseph Catanzaro
Piper Sandler
Buy
2025-02-13
Price Target
$84
Upside
+108.44%
Piper Sandler initiated coverage of Merus with an Overweight rating and $84 price target. The firm views the company's EGFRxLGR5 bispecific, petosemtamab, as "significantly de-risked" as both a monotherapy in second-line head and neck squamous cell carcinoma and in combination with pembrolizumab in first-line head and neck squamous cell carcinoma cells that express the PD-L1 protein. Piper expects additional Phase II data on the combo in 2025 to "significantly de-risk" the Phase III LiGeR-HN1 study. It believes petosemtamab is positioned to generate $3B-plus in risk-adjusted revenues by 2035 in head and neck squamous cell carcinoma alone.
Yigal Nochomovitz
Citigroup
Strong Buy
2024-12-09
Price Target
$89 → $97
Upside
+125.9%
Michael Schmidt
Guggenheim
Strong Buy
2024-12-05
Price Target
$93 → $111
Upside
+153.08%
